Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 7Uterine Cervical Neoplasms 4Endometrial Neoplasms 4Carcinoma, Ovarian Epithelial 4Fallopian Tube Neoplasms 3Platinum-resistant Ovarian Cancer 2Ovarian Diseases 2Neoplasms, Glandular and Epithelial 2Neoplasms by Site 2Neoplasms by Histologic Type 2Genital Neoplasms, Female 2Genital Diseases, Female 2Carcinoma 2Urogenital Neoplasms 1Platinum-resistant Recurrent Clear Cell Ovarian Cancer 1Platinum-resistant Ovarian Cancer (PROC) 1Ovarian Cancer Recurrent 1Neoplasms 1Endocrine System Diseases 1Advanced Endometrial Cancer 1Advanced Cervical Cancer 1Adnexal Diseases 1

Interventions

Paclitaxel 4liposomal doxorubicin 3Carboplatin 3pembrolizumab 2Bevacizumab 21-dodecylpyridoxal 2poly(I).poly(c12,U) 1mirabegron 1disitamab vedotin 1apatinib 1anlotinib 1Tocotrienols 1Platinum Compounds 1Lenalidomide 1Interferon alpha-2 1Hyperthermic Intraperitoneal Chemotherapy 1Gemcitabine 1EP-100 membrane-disrupting peptide 1Cisplatin 1AC 7700 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Cancer Recurrent × anlotinib × Gynecologic × Clear all
NCT06660511 2024-10-28

Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.

Second Xiangya Hospital of Central South University

Phase EARLY_PHASE1 Recruiting
5 enrolled
Gynecologic

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡